Jinhe Biotech announced that the inactivated vaccine for bovine nodular skin disease jointly developed by the company's subsidiary Jinhe Youben Biological Products Co., Ltd. with Jinyu Baoling Biopharmaceuticals Co., Ltd. and Luoyang Wrapson Bioengineering Co., Ltd. has been reviewed and approved as a new class of veterinary medicine by the Ministry of Agriculture and Rural Affairs, and a “New Veterinary Drug Registration Certificate” has been issued. This vaccine is used to prevent bovine nodular skin disease. It is a vaccine product approved by China that can be used for emergency prevention of this disease, and can be used as a veterinary drug required for emergency treatment of major animal diseases in the country. Jin Heyouben has obtained a temporary product approval number and is eligible for listing and sales. The application process for an official product approval number will be carried out in the future. This approval will not have a significant impact on the company's recent business performance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.